Kornimate/medical-research-clean huggingface dataset:
jump rope training and shoulder isokinetics in crossfit

Conditions: Evaluation of the Effects of Weighted Jump Rope Training on the Isokinetic Shoulder Profile in CrossFit Practitioners

Summary: the goal of this quasi-experimental clinical trial is to evaluate whether weighted jump rope (wjr) training can improve the isokinetic shoulder strength profile in male and female crossfit practitioners. the main questions it aims to answer are: * does six weeks of wjr training affect internal and external shoulder rotational peak torque relative to body mass? * does wjr influence the external/internal shoulder rotation ratio in dominant and non-dominant arms at varying angular velocities? researchers will compare pre- and post-intervention isokinetic measurements to see if wjr training leads to significant changes in shoulder strength and balance. participants will: * incorporate wjr sessions three times per week into their usual crossfit training. * undergo isokinetic testing of both shoulders at baseline and post-intervention at 60°/s, 180°/s, and 300°/s. * have their training adherence and technique monitored throughout the study.

model: single group model description: this study followed a single-arm, quasi-experimental pre-post design in which all participants underwent the same intervention: six weeks of weighted jump rope (wjr) training, integrated into their regular crossfit routines. the intervention's impact on isokinetic shoulder strength variables was assessed by comparing pre- and post-intervention measures within the same group of participants. number of arms 1, only one group received the intervention-there was no control or comparator group. masking outcomes assessor. masking description: due to the nature of the physical intervention (wjr training), blinding participants and care providers was not feasible. however, outcome assessors conducting the isokinetic tests were blinded to the study's hypotheses and group allocations to reduce measurement bias. allocation n/a. participants were not randomly assigned but instead enrolled in a single group to undergo the same intervention protocol. enrollment 18 participants

Eligibility criteria:
inclusion criteria: * self-reported crossfit training experience. accordingly, participants were classified into one of three categories (torres-banduc et al., 2021): advanced level (≥36 months of regular training, defined as ≥3 sessions of ≥120 minutes per week); intermediate level (12 to \<36 months); and beginner level (6 to \<12 months). * no injuries in the three months preceding the study. exclusion criteria: * musculoskeletal issues impacting muscle strength or the ability to undergo isokinetic shoulder evaluation. * self-reported use of anabolic steroids or other prohibited substances that might influence the study results.

Keywords: isokinetic shoulder profile weighted jump rope training rotational peak torque muscle imbalance injury prevention crossfit
momhearthealth: reducing cardiovascular risk

Conditions: Cardiovascular Diseases

Summary: this single-site research study will pilot-test a context-specific cardiovascular disease (cvd) risk prevention program, mom♥health, using two childhood centers at family health centers (fhc) at nyu langone as platforms for maternal engagement.


Eligibility criteria:
inclusion criteria: * self-identifies as a woman * is a primary caregiver of child(ren) ≤ 5 years (biological, adopted, fostered) and the child(ren) attends one of the designated childhood centers at fhc at nyu langone; * is between 21-49 years of age * is english/spanish/mandarin speaking * has the capacity and willingness to provide consent exclusion criteria: * significant cognitive impairment (evident during screening) * current participation in another behavioral clinical trial
neoadjuvant radiotherapy for malignant lacrimal sac tumors

Conditions: Malignant Tumor of Lacrimal Drainage Structure

Summary: the treatment for malignant lacrimal sac tumors is difficult and the prognosis is poor. the conventional strategy is surgical resection followed by adjuvant radiotherapy with or without concurrent chemotherapy. this approach has many drawbacks including positive surgical margins due to large tumor size, distant metastasis due to intraoperative squeeze, and implant exposure due to high doses of radiation. in previous research, the investigators innovatively adopted neoadjuvant radiotherapy (or chemoradiotherapy) and withdrew radiotherapy after surgery. preoperative radiotherapy can effectively reduce the tumor size and encapsulate the tumor in a fibrotic cyst, and therefore enables en-bloc excision of the tumor and simultaneous orbital reconstruction. this multidisciplinary approach can reduce the risk of recurrence and metastasis, lower the dose of radiation, and avoid implant exposure after reconstruction. in order to compare the long-term outcomes between neoadjuvant radiotherapy and conventional treatment approach, the investigators will prospectively recruit 94 patients with malignant lacrimal sac tumors and randomly assign these subjects into the study group (neoadjuvant radiotherapy, 47 cases) and the control group (conventional treatment, 47 cases). the primary outcomes include overall survival, disease-free survival, distant metastasis-free survival, and locoregional control at 2-year, 5-year and 10-year intervals. the secondary outcomes include ocular functions (visual acuity and diplopia, tear film stability and tear secretion, globe dystopia and motility, and corneal topography), acute and chronic radiation-related toxicity, cosmesis (medial canthal tendon dystopia and eyelid retraction), and assessment of quality of life.


Eligibility criteria:
inclusion criteria: * patients with suggestive symptoms, signs, imaging features and/or biopsy results for malignant lacrimal sac tumors * regardless of previous operations including silicone tube intubation, endoscopic dacryocystorhinostomy and incisional/needle biopsy exclusion criteria: * recurrent tumors * metastatic tumors to the lacrimal sac region * malignant lacrimal sac tumors with previous surgical excision * malignant lacrimal sac tumors with local nodal or distant metastasis * special tumor types (e.g. lymphoma) which require non-surgical treatment * large tumors (invades ≥ 2/3 depth of the orbit) which require orbital exenteration
popart'mus: prevention of post partum relapses with progestin and estradiol in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) affects 1 in 1000 people in western countries, mainly women in their childbearing years. it is an autoimmune disease of the central nervous system (cns), which results in a chronic focal inflammatory response with subsequent demyelination and axonal loss. recent prospective studies reported a significant decline by two-thirds in the rate of relapses during the third trimester of pregnancy and a significant increase by two-thirds during the first three months post-partum by comparison to the relapse rate observed during the year prior to the pregnancy (confavreux et al., 1998). these dramatic changes in the relapse rate occur at a time when the impregnation of many substances (among which, sexual steroids) is at its highest, before a dramatic decline to the pre-pregnancy levels, immediately following delivery. it may be hypothesized that sexual steroids could exert beneficial effects through a modulation of the immune state with a lowering of the pro-inflammatory lymphocyte responses of the th1 type and an enhancement of the anti-inflammatory responses of the th2 type. they may also play a direct role in the remyelination of central nervous system lesions, as they do in the peripheral nervous system. the popart'mus study is a european, multicentre, randomized, placebo-controlled and double-blind clinical trial, which aims to prevent ms relapses related to the post-partum condition, by administering high doses of progestin (nomegestrol acetate), in combination with endometrial protective doses of estradiol. treatment will be given immediately after delivery and continuously during the first three months post-partum. assuming the results of the trial to be positive, this new treatment could be considered in the relapsing-remitting phase of the disease in women afar from pregnancy and post-partum.


Eligibility criteria:
inclusion criteria: * ms according to macdonald criteria (including clinically isolated syndromes fulfilling magnetic resonance imaging \[mri\] criteria for ms diagnosis) * relapsing-remitting or secondary progressive ms * expanded disability status scale (edss) ≤ 6.0 * pregnancy ≤ 36 weeks of amenorrhea exclusion criteria: * age \< 18 years * clinical isolated syndrome not fulfilling macdonald criteria for ms * primary progressive ms * possible ms or no ms according to macdonald criteria * ongoing or previous myocardial infarction, stroke or venous thromboembolism * ongoing or previous breast cancer, or cancer of the uterus * severe liver disorder * undiagnosed genital bleeding * hypersensitivity to one of the study treatments * desire for lactation * desire for an ms disease-modifying treatment in the 24 weeks after delivery * women participating in another trial with a drug * refusal of non-hormonal contraception in the 12 weeks following delivery * consent form not signed

Keywords: multiple sclerosis. relapses. post partum. pregnancy. delivery. hormones. progesterone. estradiol. clinical trial. prevention.
the effect of endometrial scratching on patients with endometriosis

Conditions: Endometriosis; IVF

Summary: we aimed to investigate whether endometrial scratching could improve ivf outcomes by enhancing endometrial receptivity in patients with endometriosis.


Eligibility criteria:
inclusion criteria: 1.endometriosis that surgery or pathology confirmed; 2. normal ovarian reserve; 3. at least one implantation failure history exclusion criteria: 1. hydrosalpinx; 2.ademomyosis; 3.endocrine or self-immune disease; 4.serious medical condition; 5.contraindications of intrauterine operation

Keywords: endometriosis endometrial scratching endometrial receptivity ivf pregnancy rates
clinical results of arthroscopic repair for massive rotator cuff tears of 14 cases

Conditions: Rotator Cuff Tears

Summary: this study retrospectively analyzed data of 14 cases of massive rotator cuff tears who were treated with arthroscopic repair by the same doctor from october 2015 to december 2017, aiming to explore the surgical methods and clinical effects of arthroscopic repair for massive rotator cuff tears.

the preoperative and intraoperative data and patient information of 14 cases of arthroscopic repair of huge rotator cuff tears performed by deputy chief physician yang yuping of the institute of sports medicine of peking university third hospital from january 2016 to august 2017 sort out. collect and organize follow-up data on the recovery and motor function of patients 6 months after surgery and the latest follow-up (february 4 to march 3, 2018). discuss the operation method, and statistically analyze the short-term curative effect of patients undergoing the operation.

Eligibility criteria:
inclusion criteria: * diagnosed as massive rotator cuff tears and treated with arthroscopic repair from october, 2015 to december, 2017 exclusion criteria: * none

Keywords: shoulder joint arthroscopy massive rotator cuff tears
ketamine infusion vs dexmedetomidine infusion in obese patients undergoing bariatric surgery

Conditions: Morbid Obesity; Surgery

Summary: the surgeries that involve treatment of morbid obesity, i.e. bypass procedure and sleeve gastrectomy, are collectively covered under the term 'bariatric surgery'. the frequency of bariatric surgery has been increasing worldwide for patients with medically complicated obesity who have difficulty losing weight by other methods the growth of bariatric surgery is accompanied with development of anesthetic techniques to maintain patient safety and improve outcome. treatment with narcotics in obese patients has dual effect. increased use of narcotics are associated with multiple complications including postoperative nausea and vomiting (ponv) , respiratory depression and elevated risk of obstructive sleep apnea (osa) complications . on the other hand, the reduction in opioid use may result in acute post-operative pain that may limit post-surgery rehabilitation. therefore, we need to minimize opioid use and employ some other drugs which, besides having analgesia, has an opioid-sparing effect also. ketamine, an n-methyl-d-aspartate (nmda) receptor antagonist, has analgesic properties in sub-anesthetic doses. when used in low dose (0.3 to 0.5 mg/kg) by ideal body weight, it is an analgesic, anti-hyperalgesic, and prevents development of opioid tolerance. dexmedetomidine is selective α2-adrenoceptor agonist that has been used as an adjuvant to anesthetic agents in perioperative period for several adventitious profile as well as tolerated side effects . while dexmedetomidine is emerging as a beneficial adjunct to the analgesic regimen in the perioperative period, its utilization is not routinely widespread .


Eligibility criteria:
inclusion criteria: * bmi \> 35 kg/m2 * asa physical status ii \& iii (according to bmi) * undergoing laparoscopic bariatric surgery exclusion criteria: * patients refusal * asa physical status: iv (according to bmi) * history of hypersensitivity to dexmedetomidine and/or ketamine * history of substance abuse (benzodiazepines) or chronic opioid use * psychiatric or seizure disorder * uncontrolled hypertension or heart block * uncontrolled diabetes * surgical complication
clinical trial for the evaluation of safety and efficacy of drop 0.4%

Conditions: Eye Dryness

Summary: the aim of the trial is to compare the safety and efficacy of the moisturizing solution drop 0.4% with the moisturizing solution avizor eye drops 0.2% preserved in relieving the symptoms of dry eye over one month of use.


Eligibility criteria:
inclusion criteria: * male or female, aged 18 years or older, capable of freely providing informed consent for participation in the study. * signed informed consent form prior to any study-related tests. * signed data protection form prior to any study-related tests. additionally, for group 1 (non contact lens users) * ocular surface disease index (osdi) ≥ 13 * no use of contact lenses in the past month and not planning to use them during the study period. additionally, for group 2 (contact lens users) * contact lens dry eye questionnaire (cldeq-8) ≥ 12 * contact lens (cl) use with a habitual minimum use of 4 days per week and 4 hours per day in the past month. exclusion criteria: * any active ocular surface disease except for dry eye disease. * severe dry eye, defined as meeting at least one of the following criteria in at least one eye: * corneal fluorescein staining ≥ 4 on the oxford scale (0-5). * conjunctival lissamine green staining ≥ 4 on the oxford scale (0-5). * schirmer test value ≤ 2 mm. * tear stability (but) of 0 seconds. * history of ocular surgery in the last 3 months or refractive corneal surgery in the last 6 months. * history of herpetic keratitis or uveitis. * history of severe ocular infections or inflammation in the 6 months prior to the study. * history of allergies affecting the ocular surface during the study period. * patients who have started or are expected to modify the use of the following topical medications during the study (except for artificial tears/moisturizing and lubricating solutions): * calcineurin inhibitors (cyclosporine, tacrolimus, etc.) in the 12 weeks prior to the study. * corticosteroids or non steroid anti-inflammatory drugs (nsaid) in the 4 weeks prior to the study. * blood-derived treatments (autologous serum, enriched plasma, etc.), insulin, or amniotic preparations in the week prior to the study. * use of systemic medication with potential effects on the tear film that has been started or modified in the last month or is expected to change during the study. * known sensitivity or intolerance to any of the products used in the study. * subjects with clinically relevant or uncontrolled systemic diseases in the last 3 months that may interfere with study assessments or outcomes. * pregnancy or breastfeeding. lack of effective contraceptive methods in women of childbearing potential. * participation in a clinical trial within the last 30 days.

Keywords: contact lens, dry eye
comparison of sterile gauze and semi-permeable film dressing for hemodialysis central venous catheter

Conditions: Infection, Bacterial

Summary: this prospective single center rct aims to compare sterile gauze and tape versus semi-permeable film dressing on the incidence of exit-site infection, crbsis (catheter-related bloodstream infections), skin irritation, total bacterial count, dressing intactness and cost-benefit, nursing workload in hemodialysis patients with a non-tunneled hemodialysis catheter.

this prospective single center rct aims to compare sterile gauze and tape versus semi-permeable film dressing on the incidence of exit-site infection, crbsis (catheter-related bloodstream infections), skin irritation, total bacterial count, dressing intactness and cost-benefit, nursing workload in hemodialysis patients with a non-tunneled hemodialysis catheter. 154 eligible patients in our hd center will be enrolled consecutively and randomly allocated to one of the two groups according to computer-generated randomization sequences in a 1:1 ratio. experiment group use semi-permeable film as dressing in exit-site of cvc, and a sterile gauze and tape in control group. both groups share same disinfection and dressing change procedure. dressings will be replaced per hemodialysis session, or as needed. socio-demographic data and disease-related information will be collected, as well as catheterization site, physician, skin and exit status of the catheterization site at baseline. data as listed in the beginning will be recorded in the next 2 weeks follow-up at every session, such as sign of exit-site infection, crbsis (catheter-related bloodstream infections), skin irritation and dryness, dressing intactness. before the 2nd dressing change, skin around exit of cvc under dressing area will be swabbed by a cotton swab. nursing time of dressing change will be recorded by a third nurses. cost and benefit will be calculated and compared by the end.

Eligibility criteria:
inclusion criteria: * age more than 18 years; requiring hemodialysis treatment by non-tunneled cvc inserted through subclavian vein, femoral vein, internal jugular vein by nephrologists team, allowing sufficient blood flow; competent to provide informed consent. exclusion criteria: * current systemic antibiotic therapy as a result of bacteremia in the previous 21 days; pregnancy; with a known dermatitis at the exit site or known hypersensitivity to a component of either dressing; require antibiotic lock or antibiotic ointment in exit-site for infection prevention locally

Keywords: hemodialysis, semi-permeable film
new formula to predict the need for reconstructive coverage following mastectomy

Conditions: Breast Neoplasms

Summary: mastectomy is a cornerstone operative procedure in breast cancer treatment leaving a raw area behind with possibility of failure of primary closure sometimes with unavailability of facilities of reconstruction. this opened the door for this research to find a formula to predict the need of reconstruction

surgical intervention for breast cancer includes dealing with the primary tumour, added to it is the axillary dissection with variable options in both of them according to multiple factors. mastectomy represents a part of several operations as radical and modified radical mastectomy, while in others it may be the whole operation as in palliative simple mastectomy. moreover, re-excision of local recurrence is another form of surgical intervention. at the step of mastectomy or re-excision of locally recurrent disease, the challenge of closure may arise, as simple primary closure may not be possible because of wide wound gap. in this situation, reconstruction is unavoidably needed and this situation represents one of two situations in which reconstruction is indicated. as reconstruction sometimes needs certain expertise which may not be available momentarily and needs previous arrangement. moreover sometimes mastectomy exceeds the previous expectation leaving a big gap beyond simple approximation, so the investigators developed a formula to assess the need of reconstructive coverage.

Eligibility criteria:
inclusion criteria: * patients diagnosed with breast cancer primary or recurrent, early, locally advanced or metastatic, as long as they were assigned to be treated with any procedure in which mastectomy is part or all of the procedure, were included in this study. exclusion criteria: 1. any patient diagnosed with breast cancer and planned to be treated with conservative breast cancer 2. any patient whose design for excision was not regular ellipse but an irregularly tailored excision margin 3. any patient with ischemic flaps (due to excessive tension or wrong dissection) following mastectomy 4. any patient had skin disease affecting its healthiness

Keywords: post mastectomy coverage, raw area
mason heart study with mcg

Conditions: Acute Myocardial Injuries

Summary: heart disease is the number one cause of death in the united states, with over 650,000 deaths in 2019 alone. many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood pressure, high cholesterol, family history of heart disease, and diabetes. the mason heart study-mcg (mhs-mcg) registry is designed to collect magnetocardiography (mcg) scans on a select group of healthy volunteers who work for the city of mason, oh, with and without cardiac symptoms, illnesses, and/or risk factors. cardioflux is used as a noninvasive mcg tool that analyzes and records the magnetic fields of the heart to detect various forms of heart disease. there will be a 12-month duration of the study where we propose to collect screening data from approximately 250 volunteers who present to the genetesis facility for a 5-minute cardioflux mcg scan. the volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age at the time of enrollment. exclusion criteria: 1. \< 18 years of age 2. patients unable to fit into device 3. non-ambulatory patients 4. positive response on cardioflux pre-screening form 5. patients with claustrophobia or unable to lie supine for 5 minutes 6. pregnant women 7. poor candidate for follow-up (e.g. no access to phone) 8. prisoners

Keywords: ischemia acute myocardial injuries cardioflux cardiovascular disease mcg